Logo Image
|Articles|March 1, 2019

Sartorius Stedim Biotech

The Sartorius Group is a leading international partner of the biopharmaceutical industry and the research sector.

Many diseases, such as cancer, dementia, or inflammatory diseases, are still incurable. Hundreds of millions of people lack access to affordable and safe medicines. Our biopharma customers are working hard to develop new drugs to improve people’s lives. For that they need strong partners to be successful. The Sartorius Group is a leading international partner of the biopharmaceutical industry and the research sector. We are helping biotech scientists and engineers across the entire globe to develop and manufacture medications from the first idea to production so more people will have access to better medicine. 

Sartorius Stedim Biotech
INNOPHEX Booth #4249

Related to this article

View more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more